What is Anika Therapeutics's AOCI?

Anika Therapeutics (ANIK) reported AOCI of -$5.31M in Q1 2026.

How has Anika Therapeutics's AOCI changed year-over-year?

Anika Therapeutics's AOCI increased by 13.0% year-over-year, from -$6.1M to -$5.31M.

What is the long-term trend for Anika Therapeutics's AOCI?

Over 5 years (2020 to 2025), Anika Therapeutics's AOCI has grown at a 1.8% compound annual growth rate (CAGR), from -$4.54M to -$4.96M.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Anika Therapeutics ANIK AOCI

AOCI at other companies

StrykerSYK

-$583M-42.5%

VericelVCEL

-$168K-224%

Zimmer Biomet HoldingsZBH

-$190.4M+33.7%

Pacira BioSciences, Inc.PCRX

$3.46M+156%

BioventusBVS

-$2.28M-10.5%

Xtant Medical HoldingsXTNT

-$1K+99.5%

Other financials

Income statement

See full

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

See full

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

See full

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

See full

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

See full

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

See full

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Anika Therapeutics's AOCI?: Anika Therapeutics (ANIK) reported AOCI of -$5.31M in Q1 2026.
How has Anika Therapeutics's AOCI changed year-over-year?: Anika Therapeutics's AOCI increased by 13.0% year-over-year, from -$6.1M to -$5.31M.
What is the long-term trend for Anika Therapeutics's AOCI?: Over 5 years (2020 to 2025), Anika Therapeutics's AOCI has grown at a 1.8% compound annual growth rate (CAGR), from -$4.54M to -$4.96M.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.